US · ASRT
Assertio Holdings, Inc.
- Sector
- Healthcare · Drug Manufacturers - Specialty & Generic
- Headquarters
- Lake Forest, IL 60045
- Website
- assertiotx.com
Price · as of 2024-12-31
$18.47
Market cap 74.82M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $130.23 | +605.09% |
| Intrinsic Value(DCF) | $716.57 | +3,779.64% |
| Graham-Dodd Method(GD) | $2.08 | -88.77% |
| Graham Formula(GF) | $30.23 | +63.65% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | $516.00 | $3,531.68 | $11,370.28 | $48.64 | $206.43 |
| 2011 | $364.80 | $38,101.96 | $49,350.18 | $505.34 | $5,438.08 |
| 2012 | $354.60 | $2,117.45 | $63.29 | $0.00 | $712.50 |
| 2013 | $822.00 | $2,076.97 | $5,317.33 | $374.35 | $2,466.69 |
| 2014 | $1,512.00 | $9,530.00 | $191,701.79 | $1,053.22 | $25,853.97 |
| 2015 | $973.20 | $5,055.53 | $21,458.01 | $0.00 | $267.53 |
| 2016 | $943.80 | $1,801.54 | $28,740.12 | $0.00 | $0.00 |
| 2017 | $417.00 | $976.94 | $0.00 | $0.00 | $741.14 |
| 2018 | $240.60 | $870.63 | $131.56 | $380.80 | $0.00 |
| 2019 | $68.40 | $506.64 | $0.00 | $0.00 | $3,155.32 |
| 2020 | $58.80 | $1,212.10 | $0.00 | $0.00 | $685.62 |
| 2021 | $36.30 | $534.23 | $14.98 | $33.36 | $0.00 |
| 2022 | $86.10 | $1,674.32 | $42.15 | $246.95 | $1,649.71 |
| 2023 | $13.65 | $76.09 | $0.00 | $0.00 | $0.00 |
| 2024 | $11.70 | $130.23 | $9.84 | $2.08 | $30.23 |
AI valuation
Our deep-learning model estimates Assertio Holdings, Inc.'s (ASRT) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $130.23
- Current price
- $18.47
- AI upside
- +605.09%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$716.57
+3,779.64% upside
Graham-Dodd
$2.08
-88.77% upside
Graham Formula
$30.23
+63.65% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| ASRT | Assertio Holdings, Inc. | $18.47 | 74.82M | +605% | +3,780% | -89% | +64% | -3.44 | 0.61 | 0.59 | 2.82 | — | 1.83 | 68.61% | -19.59% | -17.27% | -16.66% | -29.57% | -7.56% | 0.33 | -8.05 | 1.77 | 1.34 | -2.01 | -9507.00% | -1783.00% | -4608.00% | 35.54% | 0.23 | 31.91% | 0.00% | 0.00% | 0.47% | -0.59 | 0.55 | 0.12 | -2.51 |
| ACRV | Acrivon Therapeutics, Inc… | $1.51 | 47.65M | — | — | — | — | -2.63 | 1.20 | — | -0.46 | — | 1.20 | 0.00% | — | — | -54.07% | 26706.29% | -48.11% | 0.02 | — | 10.55 | 10.43 | 0.45 | -2336.00% | — | 5579.00% | -32.26% | -3.81 | 20490.12% | 0.00% | 0.00% | 2.26% | -0.41 | -0.53 | — | 4.53 |
| FBIO | Fortress Biotech, Inc. | $3.42 | 106.15M | +410% | -82% | — | +1,342% | -0.26 | 1.41 | 0.55 | -0.49 | — | -3.51 | 63.80% | -191.38% | -79.75% | -533.80% | -308.14% | -77.53% | 3.34 | -11.12 | 1.27 | 0.95 | -0.18 | -6824.00% | -3176.00% | -3017.00% | -297.40% | -1.12 | -265.74% | 14.72% | -3.90% | 14.72% | -0.46 | -0.53 | 0.88 | -9.03 |
| INCR | InterCure Ltd. | $0.83 | 45.39M | +740% | -23% | — | +1,093% | -3.53 | 0.65 | 1.08 | -7.60 | -80.10 | 1.49 | 12.66% | -28.14% | -28.38% | -17.09% | -10.38% | -9.40% | 0.53 | -3.26 | 1.73 | 1.14 | -2.59 | 441.00% | -3282.00% | 2676.00% | -27.72% | -0.30 | -13.21% | 0.00% | 0.00% | 0.00% | -5.80 | -5.47 | 1.63 | 0.20 |
| LITS | Lite Strategy, Inc. | $1.13 | 41.55M | +12,712% | — | — | — | -1.77 | 1.66 | — | -0.60 | — | 1.66 | 0.00% | — | — | -63.84% | 545.04% | -53.45% | 0.00 | — | 13.50 | 13.30 | 1.05 | -18951.00% | -10000.00% | -5871.00% | -73.96% | -15.39 | 650.87% | 0.00% | 0.00% | 50.76% | -0.58 | -0.49 | — | -20.49 |
| LUNG | Pulmonx Corporation | $1.58 | 65.17M | +1,684% | +90% | — | — | -5.19 | 3.41 | 3.49 | -4.87 | — | 3.50 | 74.00% | -68.87% | -67.30% | -55.25% | -138.32% | -33.11% | 0.66 | -16.45 | 5.58 | 4.72 | 0.28 | -1000.00% | 2201.00% | -1414.00% | -11.27% | -1.29 | -79.07% | 0.00% | 0.00% | 0.00% | -4.29 | -7.50 | 2.95 | -1.57 |
| NTRB | Nutriband Inc. | $4.44 | 54.06M | +340% | -57% | — | — | -4.78 | 7.79 | 23.39 | -4.51 | -10.98 | 11.26 | 32.68% | -312.62% | -489.86% | -162.94% | -157.60% | -139.89% | 0.03 | -312.51 | 4.88 | 4.46 | 0.41 | 4348.00% | 262.00% | 3184.00% | -9.43% | -4.71 | -111.17% | 0.00% | 0.00% | 8.03% | -6.87 | -9.73 | 21.47 | 19.59 |
| PMVP | PMV Pharmaceuticals, Inc. | $1.70 | 90.46M | — | — | — | — | -1.08 | 0.36 | — | 1.42 | — | 0.36 | 0.00% | — | — | -29.23% | -306.66% | -26.48% | 0.01 | — | 12.22 | 11.79 | 0.54 | -2096.00% | — | -827.00% | -81.87% | -3.57 | -237.51% | 0.00% | 0.00% | 24.06% | 1.23 | 2.02 | — | -0.66 |
| TCRX | TScan Therapeutics, Inc. | $1.06 | 60.15M | +2,649% | +18% | — | +7,924% | -1.74 | 0.92 | 78.74 | -0.24 | — | 0.92 | 100.00% | -4787.68% | -4527.66% | -65.08% | -271.01% | -39.64% | 0.40 | -36.91 | 8.14 | 8.07 | 0.68 | -1618.00% | -8662.00% | 7774.00% | -51.70% | -3.08 | -230.45% | 0.00% | 0.00% | 18.21% | -0.22 | -0.25 | 10.30 | -0.75 |
| XBIT | XBiotech Inc. | $2.26 | 68.9M | — | — | — | — | -2.57 | 0.54 | — | 1.76 | -4.62 | 0.54 | 0.00% | — | — | -19.21% | -219.51% | -18.10% | 0.06 | -52.63 | 11.56 | 11.49 | 4.51 | 5556.00% | — | 6905.00% | -32.59% | -2.05 | -166.91% | 0.00% | 0.00% | 0.00% | 1.49 | 1.97 | — | 3.15 |
About Assertio Holdings, Inc.
Assertio Holdings, Inc., a specialty pharmaceutical company, provides medicines in the areas of neurology, hospital, and pain and inflammation. Its pharmaceutical products include INDOCIN, an oral solution and a suppository form for the treatment of moderate to severe rheumatoid arthritis, including acute flares of chronic disease; ankylosing spondylitis and osteoarthritis; and acute painful shoulder and gouty arthritis. It also provides CAMBIA, a non-steroidal anti-inflammatory drug (NSAID) for the treatment of migraine, nausea, photophobia, and phonophobia; Zipsor, a NSAID for relief of mild to moderate acute pain; SPRIX, a NSAID for the short term management of moderate to moderately severe pain that requires analgesia at the opioid level; and Otrexup, a single-dose auto-injector containing a prescription medicine and methotrexate that is used to treat adults with severe, active rheumatoid arthritis, and children with active polyarticular juvenile idiopathic arthritis. The company was formerly known as Assertio Therapeutics, Inc. and changed its name to Assertio Holdings, Inc. in May 2020. Assertio Holdings, Inc. was incorporated in 1995 and is headquartered in Lake Forest, Illinois.
- CEO
- Mark L. Reisenauer
- Employees
- 58
- Beta
- 0.73
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($716.57 ÷ $18.47) − 1 = +3,779.64% (DCF, example).